From a population health perspective, the need to more effectively treat neurological dysfunction is pressing, as millions of people around the world will develop a treatment-resistant or incurable neurological disease every year. The pharmaceutical industry and Big Tech are leveraging scientific and technological advancements to spur innovation, like the scaling-up of genomic approaches, novel delivery […]
GLP-1 receptor agonists are already reshaping people and healthcare systems for the management of obesity. Treatment paradigms in cardiovascular disease, sleep apnea and MASH are set to be disrupted, but it is not all gravy; weight loss post GLP-1s is often not maintained and not everyone can tolerate their side effects. We share our perspectives on the outlook for the space, including some of the implications for biopharma, service providers and investors.
Radioligand therapies (RLTs) are an emerging class of targeted therapies that could transform the way some cancers are treated. The RLT market is expected to grow significantly over the course of this decade, however several challenges will need to be overcome if the market is to achieve its full potential. In this white paper we consider the scientific, clinical, and commercial requirements for success.
Treatment paradigms in oncology are constantly evolving with more precise and efficacious therapies. One modality with strong potential are mRNA therapeutics which represent a significant growth area and could transform the way some cancers are treated. In this white paper we explore the potential for mRNA to transform the oncology landscape, considering the scientific, clinical and commercial requirements for success
How life sciences companies can use affiliations data to track non-traditional healthcare services.
Psychedelic-assisted therapies with MDMA and psilocybin are poised to transform the treatment options for a variety of hard-to-treat mental illnesses. However, psychedelics face regulatory and commercial headwinds, which manufacturers will need to navigate for psychedelics to achieve their full potential. Now may be a unique opportunity for investors to contribute to the development of psychedelics […]
An exploration within the growing CDMO space of manufacturing capabilities and efficiencies that support development of complex, innovative proteins / biologics, which continue to be increasingly pertinent and relevant in the market.
This August, ClearView Healthcare Partners had the pleasure of welcoming Laurel Sweeney and Andy Molnar for a panel discussion on the challenges and strategic approaches to secure reimbursement for digital health technologies – thank you to both for participating!
What are the key features of a propriety diagnostic tool that would enable isolation of a unique market opportunity? What is the business model that should be deployed to incentivize investment in this type of tool? In this paper, we will outline the answers to these questions and provide some examples of exciting technologies which may tap this potential.
Exploration of the value potential of digital therapeutics across biopharma portfolios to help companies gain a competitive edge
San Francisco, CA January 13 – 16, 2020 The ClearView leadership team will be attending this industry-leading healthcare investment symposium.
Current state and future trajectory of digital health including the actionable ways in which digital health can be uniquely leveraged to fill voids in the healthcare system
Hamburg, Germany November 11 – 13, 2019 Several members of the ClearView team including Kim Goh and Sam Ulin will be attending BIO-Europe 2019 in Hamburg. Please reach out if you are onsite attending – we look forward to seeing you!
Several members of leadership team will be joining the discussion with global healthcare leaders at ISPOR Europe
Principal Ryan Tubman and Head of Analytics Mike Roy present a poster at the annual meeting of the American College of Epidemiology
Principal Charles Matthews will be attending to engage in collaboration and networking
Key guiding principles for effective forecasting, common pitfalls, and how to use a forecast to develop better strategy
Presented at the 2019 BIO International Convention in Philadelphia, this talk by Sam Ulin, Managing Director, examines the drivers of value for innovators, with a focus on the technologies and applications that attracted significant funding in 2018
At BIO International Convention in Philadelphia on June 3, 2019, Managing Director Sam Ulin will give lead the Super Session talk, "What’s Next: The Landscape of Innovation in 2019 and Beyond"
As genetic testing becomes more accessible, how are companies incorporating these technologies into their strategy?
RWE has become increasingly important in supporting supplemental or conditional drug approvals. Where is the space headed?
Managing Directors Phil Kenner and Seth Berman will be attending this springtime partnering conference
What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?
The ClearView leadership team will be attending this industry-leading healthcare investment symposium
Launching a new therapy is a complex endeavor. We will review the various activities key to a successful drug launch.
How can flexibility in clinical development can be incorporated at various points along an asset’s life cycle
Navigating new challenges of market access and reimbursement for new pharmaceuticals in today's market
Recent changes in the orphan drug market access landscape and implications for pharmaceutical developers
Distinct ways that medtech companies can incorporate digital health technologies into their portfolios
Building a well thought-out plan to establish evidence of safety and of clinical utility to establish trust in a new platform